Researchers discover toxin that kills bacteria in unprecedented ways
McMaster researchers have discovered a previously unknown bacteria-killing toxin that could pave the way for a new generation of antibiotics.
The study, led by John Whitney at the Michael G. DeGroote Institute for Infectious Disease Research, shows that the bacterial pathogen Pseudomonas aeruginosa, known to cause hospital-acquired infections such as pneumonia, secretes a toxin that has evolved to kill other species of bacteria.
For Whitney, the key aspect of his discovery is not just that this toxin kills bacteria, but how it does so.
“This research is significant, because it shows that the toxin targets essential RNA molecules of other bacteria, effectively rendering them non-functional,” says Whitney, an associate professor in the department of biochemistry and biomedical sciences.
“Like humans, bacteria require properly functioning RNA in order to live.”
First study author Nathan Bullen, a graduate student in biochemistry and biomedical sciences, describes it as “a total assault on the cell” because of the number of essential pathways depend on functional RNAs.
Whitney and Bullen, together with colleagues at Imperial College London and the University of Manitoba, have studied this toxin for nearly three years to understand exactly how it functions at a molecular level.
The breakthrough, published in the journal Molecular Cell, was achieved by Bullen after rigorous experimentation on common targets of toxins, such as protein and DNA molecules, before eventually testing the toxin against RNA.
This discovery breaks well-established precedents set by protein-targeting toxins secreted by other bacteria, such as those that cause cholera and diphtheria.
Researchers say that this development holds great potential for future research that could eventually lead to new innovations that combat infection-causing bacteria.
Whitney says future antibiotic development can build on the newly discovered vulnerability.
This article was republished with permission from the Institute for Infectious Disease Research at McMaster University. Read the original.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Revealing the glycoproteome of a cancer subtype
Researchers mapped the glycoproteome of extrahepatic cholangiocarcinoma and compared it to intrahepatic tumors. Differences in sugar modifications and immune cell content suggest new biomarkers and guide development of targeted immunotherapies.

Uncovering the mechanisms of a glycosylation disorder
Mutations in OGT, an enzyme that adds sugars to proteins, cause a rare neurological disorder. Using proteomics, researchers reveal how OGT interactions with TET proteins may trigger epigenetic changes and early neural defects.

Heat shock proteins as a promising breast cancer therapeutic
Researchers unveiled isoform-specific targets on heat shock protein 90 which may be beneficial in therapeutic development.

Optimized proteomic analysis of preserved biological tissue samples
Researchers have developed an optimized workflow for analyzing formalin-fixed paraffin-embedded tissue. This workflow provides an enhanced collection of unique proteins and phosphorylation sites for more detailed analysis of biological samples.

Blood proteomics reveals fungal infection signatures for faster diagnosis
Whole-blood proteomics identifies more than 3,000 host and 160 fungal proteins during cryptococcal infection, offering potential biomarkers for faster diagnosis and improved monitoring without invasive spinal taps.

When things get SAPpy: Novel insights into complement
Researchers have defined interactions between an innate immune protein and two of its known binding partners. They identified potential areas of crosstalk between the two binding interactions.